April 01, 2021
A medication adherence intervention led by community pharmacists in Spain improved clinical outcomes in patients with hypertension, asthma, and chronic obstructive pulmonary disease (COPD), according to a study published online ahead of print in BMJ Quality & Safety.
“Significant increases in the percentage of patients adhering to their dosing regimen and improvements in COPD outcomes were evident after 3 months of follow-up,” researchers reported. “In the case of asthma outcomes and diastolic blood pressure, significant improvements were observed after 5 months.”
The 6-month cluster randomized clinical trial involved 98 community pharmacies and 1038 patients with hypertension, asthma, and COPD. Patients in the intervention group received a pharmacist-led medication adherence management intervention based on evidence-based behavioral change frameworks. Patients in the control group received usual care.
Patients in the intervention group had a 5.12 odds ratio of being adherent to medication regimens after 6 months, according to the study. By the end of the trial, patients who received the pharmacist-led intervention had lower diastolic blood pressure levels (−2.88 on average), lower Clinical COPD Questionnaire scores (−0.50 on average), and lower Asthma Control Questionnaire scores (−0.28 on average) compared with patients who received usual care.
“Findings of this study provide evidence on the effectiveness of a patient-targeted intervention and support the future implementation of a medication adherence management service in regular practice,” researchers wrote.
Torres-Robles A, Benrimoj SI, Gastelurrutia MA, et al. Effectiveness of a medication adherence management intervention in a community pharmacy setting: a cluster randomised controlled trial [published online ahead of print, 2021 Mar 29]. BMJ Qual Saf. 2021;bmjqs-2020-011671. doi:10.1136/bmjqs-2020-011671